Trials / Completed
CompletedNCT04932252
A Study of A4368 in Healthy Subjects
A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximal Tolerable Dose and to Evaluate the Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Doses of A4368 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Autophagy Sciences, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A4368 is the autophagy activator that is being developed for the treatment of nonalcoholic steatohepatitis. The goal of the study is to assess the safety, tolerability, and pharmacokinetics in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A4368 or placebo tablet | orally administered |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2022-07-25
- Completion
- 2022-07-25
- First posted
- 2021-06-21
- Last updated
- 2023-01-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04932252. Inclusion in this directory is not an endorsement.